Lupin to market Lilly’s rapid-acting Insulin analog Lispro under the brand name Eglucent
Lupin and Eli Lilly and Company (India) announced an expansion of their partnership in India with the launch of Eglucent, a new brand of Lilly’s rapid-acting insulin analog Lispro.
According to the agreement, Lupin will market and sell Eglucent through its own speciality field force while Lilly will be responsible for manufacturing and import. Lilly will continue to sell Lispro under the brand name Humalog through its existing channels. Lupin had earlier collaborated with Lilly (July, 2011) to promote and distribute Lilly’s Huminsulin range of products in India and Nepal.
Eglucent is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type I and II diabetes. Eglucent will be available in the Indian market in both, the cartridge and disposable pen form. Eglucent is a prescription drug that should be taken only when prescribed by a registered physician. It is intended as an adjunct to diet and exercise to improve the glycemic control.
“The intent of this launch, which is the first for Lilly in the entire Emerging Markets region, is to increase the reach of analog insulin Lispro to more patients and healthcare professionals. We believe this is a big step in our journey to help fight the rising disease burden in India,” said Edgard Olaizola, MD, Lilly India.
Shakti Chakraborty, Group President, India Region Formulations, Lupin said, “We are excited about expanding our partnership with Eli Lilly with the launch of Eglucent and the progress that we together have made to combat the rising incidence of Diabetes in India. Our entry into the rapid-acting insulin analog segment will not only bolster our existing diabetes portfolio but will also go a long way in strengthening our position in the Indian pharma market.”
EP News Bureau